4 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
Show:
| TripSit | Pharmacology | DrugCentral | DailyMed | ||
|---|---|---|---|---|---|
| Classification | |||||
| Class / category | — | — | — | ||
| Also known as | wellbutrinzybanamfebutamone | — | — | — | |
| Safety | |||||
| Duration | |||||
| Onset | 15–90 minutes | — | — | — | |
| After-effects | 1–6 hours | — | — | — | |
| Pharmacology | |||||
| Receptor activity | — | — | SLC6A3SLC6A2ADRA1ACYP2C19CYP2D6Pgrmc1CHRNA7CHRNB2CHRNB4SLC6A4 | — | |
| Half-life | — | 24 hours The half-life of bupropion in the terminal phase averages about 14 hours (range: 8-24 hours) following single doses; with multiple dosing, the half-life of bupropion in the terminal phase reportedly averages 21 hours (range: 8-39 hours). In a limited number of geriatric patients with a major depressive episode, the half-life of bupropion in the terminal phase averaged about 34 hours after a single oral dose of the drug. | — | — | |
| Protein binding | — | In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg per mL. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion. | — | — | |
TripSit summary
A frequently prescribed atypical antidepressant. Occasionally prescribed as an aid to smoking cessation. May lower seizure threshold in predisposed individuals. Poorly understood mechanism of action, probably an NDRI. Avoid combination with other drugs.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.